- FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyoutGSK's $10.6 billion acquisition of Nuvalent is delivering surprisingly early results. The FDA on Wednesday approved one of Nuvalent's lung cancer medicines two months earlier than projected, and…Endpoints · 5d ago↗ source
- Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug<figure><div><img src="https://imgproxy.divecdn.com/8hRa8ccyqK4EhEh4oXaIz1XS7XE4MZBhJhutfBJVSSU/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNzUyMzcxMjg5LmpwZ…BioPharma Dive · 5d ago↗ source
- Arrowhead’s gene silencer competitive with Ionis’ in triglyceride diseaseArrowhead Pharmaceuticals’ lipid-lowering drug has hit in two late-stage trials that could expand its use into a much wider population. Data shared Wednesday showed that Arrowhead’s gene silencer…